LinkedIn Co-Founder Launches AI Startup for Cancer Treatment Discovery
Reid Hoffman, co-founder of LinkedIn and venture capitalist at Greylock Partners, has established Manas AI, a startup utilizing AI to accelerate cancer treatment discovery.
Proprietary AI Platform
Manas AI employs a proprietary AI platform to enhance the drug discovery process. It identifies potential drug candidates with unprecedented speed and precision, enabling efficient progress to clinical trials. The startup initially targets breast cancer, prostate cancer, and lymphoma, with an eventual expansion to other autoimmune diseases and rare conditions.
Collaboration and Funding
The startup acquired nearly $25 million in seed funding led by General Catalyst, with support from Greylock and other investors in the life sciences and technology sectors. Hoffman has also invested personally. Additionally, Manas AI has partnered with Microsoft for cloud computing services.
Cancer Researcher Collaboration
Hoffman co-founded Manas AI with cancer researcher Dr. Siddhartha Mukherjee, Pulitzer Prize winner for "The Emperor of all Maladies: A Biography of Cancer." Dr. Mukherjee emphasized their mission to revolutionize drug discovery and reduce the time and cost involved.
Wave of AI in Drug Discovery
Manas AI joins a growing number of tech companies leveraging AI for drug discovery. Google DeepMind's CEO, Demis Hassabis, has announced that drugs designed by AI are expected to enter clinical trials later this year.
Contributors acknowledge the efforts of William Gavin. Stay informed by visiting Facebook, Twitter, and Instagram for news updates.